Children and young people with chronic health conditions in the Midland region (2022)
Abstract
This report from the New Zealand Child and Youth Epidemiology Service (NZCYES) aims to present data and information to assist in commissioning services that can contribute to improved health and wellbeing of children and young people in each locality. This 2022 report focuses on children and young people with long-term health conditions. Some of these conditions are present at birth, and others develop during childhood and adolescence. Once diagnosed, the conditions may be ongoing, long term, or recurrent. Children with these conditions usually require lifelong health care, and may experience limitations in day-to-day activities and interrupted education. In addition, management of the conditions can impact on whānau wellbeing. Adolescence usually signals the need for children with long-term conditions to transition into adult health services. This is a key aspect of health service commissioning and delivery in which data are needed to monitor positive and beneficial transitions that promote equity and wellbeing into adulthood. The following indicators included in this report were identified in the indicator framework developed for the NZCYES through literature review and consultation with the child health workforce, and by ongoing discussion with child health service providers: • Cystic fibrosis • Diabetes • Cerebral palsy • Epilepsy • Bronchiectasis (non-cystic fibrosis) • Inflammatory bowel disease Administrative data were extracted from National Collections, Surveys and…
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.